NTLA vs EDIT
NTLA and EDIT side by side — valuation & fundamentals (public data).
Key statistics
| Metric | NTLAINTELLIA THERAPEUTICS, INC. | EDITEDITAS MEDICINE, INC. |
|---|---|---|
| Market cap | $1.73B | $418.51M |
| P/S | 25.6x | 10.3x |
| Revenue growth (YoY) | 16.9% | 25.4% |
| Earnings growth (YoY) | 20.5% | 32.5% |
| EBIT margin | -651.7% | -394.9% |
| ROE | -56.7% | -152.0% |
| 1y total return | -2.2% | -11.1% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: NTLA vs EDIT
| Metric | NTLA | EDIT |
|---|---|---|
| End value | $5.8K | $1.1K |
| Total return | -42.0% | -88.8% |
| CAGR | -5.1% | -19.1% |
| Volatility | 78.3% | 83.6% |
| Sharpe | 0.27 | 0.10 |
| Sortino | 0.40 | 0.15 |
| Max drawdown | -96.5% | -98.9% |
Based on 2600 common trading days, 2016-06-30 → 2026-11-02 · risk-free 4.16% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)